Teva Pharma Industries Stock Analysis

TEVA Stock  USD 16.50  0.31  1.84%   
Teva Pharma Industries is overvalued with Real Value of 12.44 and Target Price of 10.56. The main objective of Teva Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Teva Pharma Industries is worth, separate from its market price. There are two main types of Teva Pharma's stock analysis: fundamental analysis and technical analysis.
The Teva Pharma stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Teva Pharma's ongoing operational relationships across important fundamental and technical indicators.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Teva Stock Analysis Notes

About 58.0% of the company shares are owned by institutional investors. The book value of Teva Pharma was at this time reported as 5.35. The company has Price/Earnings To Growth (PEG) ratio of 1.29. Teva Pharma Industries recorded a loss per share of 0.85. The entity last dividend was issued on the 27th of November 2017. The firm had 2:1 split on the 1st of July 2004. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. Teva Pharmaceutical is traded on New York Stock Exchange in the United States. To find out more about Teva Pharma Industries contact Kare Schultz at 972 3 914 8213 or learn more at https://www.tevapharm.com.

Teva Pharma Quarterly Total Revenue

4.33 Billion

Teva Pharma Industries Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Teva Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Teva Pharma Industries or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Teva Pharma generated a negative expected return over the last 90 days
Teva Pharma Industries currently holds 20.15 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 15.85 B. Net Loss for the year was (615 M) with profit before overhead, payroll, taxes, and interest of 6.97 B.
Teva Pharma has a strong financial position based on the latest SEC filings
About 58.0% of Teva Pharma shares are owned by institutional investors
Latest headline from finance.yahoo.com: Tamiflu Market Set to Surpass 2.7 Billion by 2034, Driven by Rising Influenza Cases and Key Developments

Teva Pharma Industries Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Teva Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
31st of January 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Teva Largest EPS Surprises

Earnings surprises can significantly impact Teva Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2001-04-24
2001-03-310.090.10.0111 
2000-05-04
2000-03-310.070.080.0114 
1998-05-11
1998-03-310.060.05-0.0116 
View All Earnings Estimates

Teva Pharma Environmental, Social, and Governance (ESG) Scores

Teva Pharma's ESG score is a quantitative measure that evaluates Teva Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Teva Pharma's operations that may have significant financial implications and affect Teva Pharma's stock price as well as guide investors towards more socially responsible investments.

Teva Pharma Thematic Classifications

In addition to having Teva Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Israel Wall Street Idea
Israel Wall Street
Large Israel companies traded on major USA exchanges
Adviser Favorites Idea
Adviser Favorites
Equities that are favored by financial advisors

Teva Stock Institutional Investors

Shares
Slate Path Capital Lp2024-09-30
13.7 M
Morgan Stanley - Brokerage Accounts2024-09-30
13.6 M
Millennium Management Llc2024-09-30
11.8 M
Pointstate Capital Lp2024-09-30
9.8 M
Geode Capital Management, Llc2024-09-30
8.8 M
Glenview Capital Management Llc2024-09-30
8.5 M
Renaissance Technologies Corp2024-09-30
8.1 M
Australiansuper Pty Ltd2024-09-30
7.9 M
Viking Global Investors Lp2024-09-30
7.6 M
Fmr Inc2024-09-30
62.7 M
Blackrock Inc2024-06-30
43 M
Note, although Teva Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Teva Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 19.66 B.

Teva Profitablity

The company has Profit Margin (PM) of (0.06) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.03)(0.03)
Return On Capital Employed 0.01  0.01 
Return On Assets(0.01)(0.01)
Return On Equity(0.07)(0.07)

Management Efficiency

Teva Pharma Industries has return on total asset (ROA) of 0.0556 % which means that it generated a profit of $0.0556 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1752) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. In addition to that, Return On Capital Employed is expected to decline to 0.01. At present, Teva Pharma's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 3.42, whereas Total Assets are forecasted to decline to about 26.4 B.
Last ReportedProjected for Next Year
Book Value Per Share 7.26  8.49 
Tangible Book Value Per Share(12.90)(12.26)
Enterprise Value Over EBITDA 18.22  14.50 
Price Book Value Ratio 1.56  1.48 
Enterprise Value Multiple 18.22  14.50 
Price Fair Value 1.56  1.48 
Enterprise Value38.6 B40.5 B
The leadership approach at Teva Pharma's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Operating Margin
0.2318
Profit Margin
(0.06)
Beta
0.868
Return On Assets
0.0556
Return On Equity
(0.18)

Technical Drivers

As of the 15th of December 2024, Teva Pharma has the Risk Adjusted Performance of (0.04), coefficient of variation of (1,642), and Variance of 3.56. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Teva Pharma Industries, as well as the relationship between them.

Teva Pharma Industries Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Teva Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Teva Pharma Industries. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Teva Pharma Industries Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Teva Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Teva Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Teva Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Teva Pharma Outstanding Bonds

Teva Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Teva Pharma Industries uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Teva bonds can be classified according to their maturity, which is the date when Teva Pharma Industries has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Teva Pharma Predictive Daily Indicators

Teva Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Teva Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Teva Pharma Corporate Filings

F3
4th of December 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
F4
21st of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
12th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
8K
6th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
4th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
13th of August 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
5th of August 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
8K
31st of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Teva Pharma Forecast Models

Teva Pharma's time-series forecasting models are one of many Teva Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Teva Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Teva Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Teva Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Teva shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Teva Pharma. By using and applying Teva Stock analysis, traders can create a robust methodology for identifying Teva entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.04)(0.04)
Operating Profit Margin 0.03  0.03 
Net Loss(0.04)(0.03)
Gross Profit Margin 0.48  0.38 

Current Teva Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Teva analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Teva analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.56Strong Buy12Odds
Teva Pharma Industries current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Teva analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Teva stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Teva Pharma Industries, talking to its executives and customers, or listening to Teva conference calls.
Teva Analyst Advice Details

Teva Stock Analysis Indicators

Teva Pharma Industries stock analysis indicators help investors evaluate how Teva Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Teva Pharma shares will generate the highest return on investment. By understating and applying Teva Pharma stock analysis, traders can identify Teva Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow2.8 B
Long Term Debt18.2 B
Common Stock Shares Outstanding1.1 B
Total Stockholder Equity7.5 B
Tax Provision-7 M
Quarterly Earnings Growth Y O Y0.4
Property Plant And Equipment Net6.1 B
Cash And Short Term Investments3.2 B
Cash3.2 B
Accounts Payable2.6 B
Net Debt16.9 B
50 Day M A17.5092
Total Current Liabilities12.2 B
Other Operating Expenses12.7 B
Non Current Assets Total31 B
Forward Price Earnings5.9773
Non Currrent Assets Other463 M
Stock Based Compensation121 M

Complementary Tools for Teva Stock analysis

When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum